Metadata
Author: Giga-fren
Data
English[en]
(Quebec City) announced that its North American partner for perifosine, Keryx Biopharmaceuticals, Inc. disclosed that data presented at the annual meeting of the American Society of Clinical Oncology (ASCO) in Orlando, Florida, demonstrated the tolerability and potential efficacy of perifosine in the treatment of patients with biochemically recurrent hormone-sensitive prostate cancer (HSPC).
French[fr]
(Québec) a fait savoir que son partenaire nord-américain, Keryx Biopharmaceuticals, Inc. a annoncé le dévoilement des résultats d'une étude clinique de phase II démontrant l'innocuité et l'efficacité potentielle de la perifosine chez des patients atteints d'un cancer de la prostate hormonodépendant et biochimiquement récurrent.